Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Covaxin effective against the Brazilian variant: ICMR-NIV study

Covaxin effective against the Brazilian variant: ICMR-NIV study



In a new study, researchers from the Indian Council for Medical Research – National Institute of Virology have found that Covaxin is effective against the Brazilian version (B.1.128.2).

This is close to their recent study, which also suggests that Covaxin is effective against both the UK variant and the Indian variant (double mutant) B.1.617.

India currently uses two vaccines, Covid 19, Covaxin from Bharat Biotech and Covishield from the Serum Institute in India, to vaccinate people across the country.

There is evidence that the local Covid-19 jab Covaxin in the country is proving effective against some options.

Dr. Anthony Fauci, who is chief adviser to US President Joe Biden on the Covid pandemic, cites recent ICMR Phase 3 clinical trials of Covaxin that claim that the vaccine neutralizes many variants of SARS-CoV-2 and effectively neutralizes the double mutant strain (B1

617) as well.

In this new study, published in the bioRxiv pre-press on April 30, the researchers showed that Covaxin was effective against the Brazilian version (B.1.1.28.2).

A new study shows that the two-dose regimen of Covaxin significantly increases the titer of IgG (antibodies) and neutralizes the efficacy of the Brazilian variant and variant D614G compared to that observed in natural infection.

Led by NIV scientists Gajanan Sapkal, Pragya Yadav, Priya Abraham and others, they said it was a strong neutralization of variants B1 and B.1.1.28.2 among vaccine recipients.

The researchers determined the IgG immune response and neutralizing activity of 19 samples of reconstituted sera obtained from reconstituted cases of COVID-19 and confirmed for Great Britain (B.1.1.7), South Africa (B.1.351) and Brazil (B.1.1. ) variants (15-113 days after a positive test) and from 42 participants immunized with inactivated vaccine Covid-19, BBV 152 (Covaxin) as part of a phase II clinical trial (two months after the second dose).

The response has been observed in recovered cases, but the study found a better response than samples from beneficiaries of the Covaxin vaccine, the researchers said.

India has reported cases of SARS-CoV-2 UK variant (B.1.1.7). Recently, the variant with South Africa (B.1.351) and the Brazilian variant P2 (B.1.1.28.2) were also found for international travelers traveling to India from abroad.

The impact on the emergence of these new variants on the efficacy of currently available COVID-19 vaccines or the neutralizing ability of sera of individuals naturally infected with earlier circulating strains is currently being investigated.

Although some vaccines appear to be effective against the British variant, efficacy against the South African variant has been shown to be less effective.

According to a recent NCDC report, of the 15,000 sequenced samples, 11 percent include these anxiety options.

By the first week of April, the number of cases of variants of the COVID virus in the UK, South Africa and Brazil had reached 948.


Source link